Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer
Phase III
· Site: SITE005 (FRA) (Dr. Muller)
· consented 2022-08-21
Adverse events
6
Serious AEs
1
Open data queries
0
Luna dropout signal
–
Adverse events
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-13 (study day 7); relationship: not assessed
severe
serious
assessed
2026-08-18
Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 11); relationship: N; serious criteria: hospitalization
moderate
assessed
2026-08-18
Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-25 (study day 19); relationship: not assessed
moderate
assessed
2026-08-18
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 37); relationship: N
moderate
assessed
2026-08-18
Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 59); relationship: not assessed
mild
assessed
2026-08-18
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 64); relationship: not assessed
Data queries
No data queries.
☾ Luna engagement
This participant doesn't use Luna.